Usha Krishnan

Dr. Usha Krishnan

1. Department of Paediatric Gastroenterology, Sydney Children’s Hospital, High Street, Randwick, NSW 2031, Australia
+1

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2018 in Genome Medicine
Verified
Journal Article
Open access
PDF file
NZNa Zhu
Na Zhu
CWCarrie Welch
Carrie Welch
JWJiayao Wang
Jiayao Wang
PAPhilip M. Allen
Philip M. Allen
CGClaudia Gonzaga-Jauregui
Claudia Gonzaga-Jauregui
WCWendy K. Chung
Wendy K. Chung
Pulmonary arterial hypertension (PAH) is a rare disease characterized by distinctive changes in pulmonary arterioles that lead to progressive pulmonary arterial pressures, right-sided heart failure, and a high mortality rate. Up to 30% of adult and 75% of pediatric PAH cases are associated with congenital heart disease (PAH-CHD), and the underlying etiology is largely unknown. There are no known major risk genes for PAH-CHD. To identify novel genetic causes of PAH-CHD, we performed whole exome sequencing in 256 PAH-CHD patients. We performed a case-control gene-based association test of rare deleterious variants using 7509 gnomAD whole genome sequencing population controls. We then screened a separate cohort of 413 idiopathic and familial PAH patients without CHD for rare deleterious variants in the top association gene. We identified SOX17 as a novel candidate risk gene (p = 5.5e−7). SOX17 is highly constrained and encodes a transcription factor involved in Wnt/β-catenin and Notch signaling during development. We estimate that rare deleterious variants contribute to approximately 3.2% of PAH-CHD cases. The coding variants identified include likely gene-disrupting (LGD) and deleterious missense, with most of the missense variants occurring in a highly conserved HMG-box protein domain. We further observed an enrichment of rare deleterious variants in putative targets of SOX17, many of which are highly expressed in developing heart and pulmonary vasculature. In the cohort of PAH without CHD, rare deleterious variants of SOX17 were observed in 0.7% of cases. These data strongly implicate SOX17 as a new risk gene contributing to PAH-CHD as well as idiopathic/familial PAH. Replication in other PAH cohorts and further characterization of the clinical phenotype will be important to confirm the precise role of SOX17 and better estimate the contribution of genes regulated by SOX17.

1 June 2018 in The Journal of Pediatrics
Verified
Journal Article
Closed access
JKJohn P. Kinsella
John P. Kinsella
RSRobin H. Steinhorn
Robin H. Steinhorn
MMMary P. Mullen
Mary P. Mullen
RHRachel K. Hopper
Rachel K. Hopper
RKRoberta L. Keller
Roberta L. Keller
SASteven H. Abman
Steven H. Abman

1 March 2016 in The Journal of Pediatrics
Verified
Journal Article
Closed access
JKJohn P. Kinsella
John P. Kinsella
RSRobin H. Steinhorn
Robin H. Steinhorn
Usha KrishnanUsha Krishnan
Usha Krishnan
JFJeffrey A. Feinstein
Jeffrey A. Feinstein
IAIan Adatia
Ian Adatia
SASteven Abman
Steven Abman

1 February 2019 in The Journal of Pediatrics
Verified
Journal Article
Closed access
JCJennifer L. Cohen
Jennifer L. Cohen
SNShannon N. Nees
Shannon N. Nees
GVGerson A. Valencia
Gerson A. Valencia
BRBerman Rosenzweig
Berman Rosenzweig
Usha KrishnanUsha Krishnan
Usha Krishnan

1 July 2018 in The Journal of Pediatrics
Verified
Journal Article
Closed access
CBCarl H. Backes
Carl H. Backes
ENErin Nealon
Erin Nealon
AAAimee K. Armstrong
Aimee K. Armstrong
CCClifford L. Cua
Clifford L. Cua
CMCourtney Mitchell
Courtney Mitchell
JBJeffrey Bridge
Jeffrey Bridge

1 December 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
MLMatthew J. Lewis
Matthew J. Lewis
BABrett R. Anderson
Brett R. Anderson
MFMichael Fremed
Michael Fremed
MAMelissa Argenio
Melissa Argenio
Usha KrishnanUsha Krishnan
Usha Krishnan
JWJoyce Woo
Joyce Woo
Background: We sought to assess the impact and predictors of coronavirus disease 2019 (COVID‐19) infection and severity in a cohort of patients with congenital heart disease (CHD) at a large CHD center in New York City. Methods and Results: We performed a retrospective review of all individuals with CHD followed at Columbia University Irving Medical Center who were diagnosed with COVID‐19 between March 1, 2020 and July 1, 2020. The primary end point was moderate/severe response to COVID‐19 infection defined as (1) death during COVID‐19 infection; or (2) need for hospitalization and/or respiratory support secondary to COVID‐19 infection. Among 53 COVID‐19‐positive patients with CHD, 10 (19%) were <18 years of age (median age 34 years of age). Thirty‐one (58%) had complex congenital anatomy including 10 (19%) with a Fontan repair. Eight (15%) had a genetic syndrome, 6 (11%) had pulmonary hypertension, and 9 (17%) were obese. Among adults, 18 (41%) were physiologic class C or D. For the entire cohort, 9 (17%) had a moderate/severe infection, including 3 deaths (6%). After correcting for multiple comparisons, the presence of a genetic syndrome (odds ratio [OR], 35.82; P =0.0002), and in adults, physiological Stage C or D (OR, 19.38; P =0.002) were significantly associated with moderate/severe infection. Conclusions: At our CHD center, the number of symptomatic patients with COVID‐19 was relatively low. Patients with CHD with a genetic syndrome and adults at advanced physiological stage were at highest risk for moderate/severe infection.